CoChat

Anti-Inflammation and Anti-Oxidation: The Key to Unlocking the Cardiovascular Potential of SGLT2 Inhibitors and GLP1 Receptor Agonists

Open access

The DOI matches its Crossref record; 103 of the 107 references it cites were found in a registry or an index.

Abstract

Type 2 diabetes mellitus (T2DM) is a prevalent and complex metabolic disorder associated with various complications, including cardiovascular diseases. Sodium-glucose co-transporter 2 inhibitors (SGLT2i) and glucagon-like peptide 1 receptor agonists (GLP1-RA) have emerged as novel therapeutic agents for T2DM, primarily aiming to reduce blood glucose levels. However, recent investigations have unveiled their multifaceted effects, extending beyond their glucose-lowering effect. SGLT2i operate by inhibiting the SGLT2 receptor in the kidneys, facilitating the excretion of glucose through urine, leading to reduced blood glucose levels, while GLP1-RA mimic the action of the GLP1 hormone, stimulating glucose-dependent insulin secretion from pancreatic islets. Both SGLT2i and GLP1-RA have shown remarkable benefits in reducing major cardiovascular events in patients with and without T2DM. This comprehensive review explores the expanding horizons of SGLT2i and GLP1-RA in improving cardiovascular health. It delves into the latest research, highlighting the effects of these drugs on heart physiology and metabolism. By elucidating their diverse mechanisms of action and emerging evidence, this review aims to recapitulate the potential of SGLT2i and GLP1-RA as therapeutic options for cardiovascular health beyond their traditional role in managing T2DM.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3390/antiox13010016

Cites

103 of 103 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 SGLT2i and GLP1-RA cardiometabolic effects. The violet boxes represent the action of SGLT2i, while the yellow boxes represent the action of GLP1-RA. The arrow pointing downwards reflect a downregulation of the mechanisms, while upwards arrows indicate an upregulation of the mechanisms. AF: atrial fibrillation; AFL: atrial flutter; EPO: erythropoietin; GLP1-RA: glucagon-like peptide 1 receptor agonist; SGLT2i: sodium-glucose co-transporter 2 inhibitors.
Figure 1 SGLT2i and GLP1-RA cardiometabolic effects. The violet boxes represent the action of SGLT2i, while the yellow boxes represent the action of GLP1-RA. The arrow pointing downwards reflect a downregulation of the mechanisms, while upwards arrows indicate an upregulation of the mechanisms. AF: atrial fibrillation; AFL: atrial flutter; EPO: erythropoietin; GLP1-RA: glucagon-like peptide 1 receptor agonist; SGLT2i: sodium-glucose co-transporter 2 inhibitors.CC BY · PubMed Central
Figure 2 Multi-receptor agonists. The green box and arrows represent the action of GIP, the blue box and arrows represent the action of GLP1, while the orange box and arrows represent the action of GCG. The arrow pointing downwards reflect a downregulation of the mechanisms, while upwards arrows indicate an upregulation of the mechanisms. CV: cardiovascular; GIP: glucose-dependent insulinotropic polypeptide; GCG: glucagon; GLP1: glucagon-like peptide 1.
Figure 2 Multi-receptor agonists. The green box and arrows represent the action of GIP, the blue box and arrows represent the action of GLP1, while the orange box and arrows represent the action of GCG. The arrow pointing downwards reflect a downregulation of the mechanisms, while upwards arrows indicate an upregulation of the mechanisms. CV: cardiovascular; GIP: glucose-dependent insulinotropic polypeptide; GCG: glucagon; GLP1: glucagon-like peptide 1.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 42

Metadata

Authors
Myasoedova, V. A., Bozzi, M., Valerio, V., Moschetta, D., Massaiu, I., Rusconi, V., Di Napoli, D., Ciccarelli, M., Parisi, V., Agostoni, P., Genovese, S., & Poggio, P.
Affiliations
  • Centro Cardiologico Monzino (IT)
  • Department of Medicine, Surgery and Dentistry, University of Salerno, 84084 Fisciano, Italy
  • University of Salerno (IT)
  • Federico II University Hospital (IT)
Corresponding author
Poggio, Paolo
Venue
Antioxidants
Publisher
MDPI AG
Published
2023-12-20
Volume
13
Issue
1
Pages
16
ISSN
2076-3921 (ISSN-L)
OpenAlex
W4389991782
Cited by
35
References
107
Citations by year
2026: 12 · 2025: 13 · 2024: 10
FWCI
1.26
Type
journal article
Language
en
Open access
Locations
  • Antioxidants (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • Archivio Istituzionale della Ricerca (Universita Degli Studi Di Milano) (submittedVersion, other-oa)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
  • European Union—Next Generation EU—NRRP M6C2—Investment 2.1 Enhancement and strengthening of biomedical research in the NHS (PNRR-MAD-2022-12376009, FPF-14)
  • Italian Ministry of Health (Ricerca Corrente to Centro Cardiologico Monzino IRCCS) (PNRR-MAD-2022-12376009, FPF-14)
  • Fondazone Gigi & Pupa Ferrari ONLUS (PNRR-MAD-2022-12376009, FPF-14)
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiovascular Function and Risk Factors
Keywords
SGLT2 inhibitors, GLP-1 receptor agonists, type 2 diabetes, cardiovascular disease, anti-inflammatory activity, antioxidant activity, cardioprotection, glucose-lowering therapy, cardiac physiology, myocardial metabolism

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.